谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

221 SYNERGY-1: A Phase 1, First-in-human, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability, Immunogenicity, PK and PD Study of KP104 in Escalating Single and Multiple Doses

Paul Wabinitz,Jay Ma,Ping Tsui,Helen Fu, Chaomei He,Jingtao Wu, Qing Yu Christina Weng, Jon Rankin,Wenru Song,Nicholas Farinola,Richard Lee

Immunobiology（2023）

引用 0|浏览2
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要